In a recently published study, a team of researchers led by Dr. Giovanni Mancardi from the University of Genoa conducted a phase II clinical trial to compare the effectiveness of conventional multiple sclerosis [MS] therapy to intravenous stem cell transplantation. Throughout the four year trial, the team found that, in addition to significantly decreasing disease progression and brain damage compared to MS drug mitoxantrone [MTX], the transplanted stem cells had migrated into the patients’ bone marrow and stimulated the generation of new, non-harmful immune cells, essentially resetting the immune system.
The initial success of the study demonstrates the profound improvements that regenerative medicine, which relies on the body’s own repair and maintenance systems, can make on the lives of patients suffering from severe disease, trauma and injury. As stated by Dr. Mancardi, “More research is needed… but it’s very exciting to see that this treatment may be so superior to a current treatment for people with severe MS that [are] not responding well to standard treatments.”
As personalized regenerative medicine advances, autologous stem cells will become an invaluable resource to families and individuals who seek to ensure that they will have access to the best in medical care should the need for it arise. One of the most convenient and affordable sources for recovering and banking your own stem cells is dental stem cells. To learn more about how to bank dental stem cells for use in future therapies and treatments, visit StemSave or call 877-783-6728 (877-StemSave) today.
To view the full article, click here.
The Future of Regenerative Medicine is Now.™